Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Acquires Synthetic Nucleic Acid Manufacturer SynPro

NEW YORK, April 17 (GenomeWeb News) - Agilent Technologies said today that it has acquired SynPro, a privately held manufacturer of synthetic nucleic acids based in Boulder, Colo.

 

Financial details of the agreement were not disclosed.

 

SynPro manufactures short synthetic DNA and RNA molecules. Agilent estimated that the size of the RNA and DNA synthesis market is currently around $700 million, with anticipated growth in the range of 10 to 20 percent per year.

 

SynPro will join Agilent's New Business Group. Agilent has hired 22 employees from the firm.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.